Tandem Diabetes Care, Inc. (TNDM)
20.42
-0.14
(-0.68%)
USD |
NASDAQ |
Sep 03, 16:00
20.42
0.00 (0.00%)
After-Hours: 20:00
Tandem Diabetes Care Research and Development Expense (Annual) : 174.84M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 174.84M |
| December 31, 2024 | 184.17M |
| December 31, 2023 | 155.85M |
| December 31, 2022 | 126.78M |
| December 31, 2021 | 80.41M |
| December 31, 2020 | 54.32M |
| December 31, 2019 | 39.43M |
| December 31, 2018 | 29.23M |
| Date | Value |
|---|---|
| December 31, 2017 | 20.66M |
| December 31, 2016 | 18.81M |
| December 31, 2015 | 16.96M |
| December 31, 2014 | 15.79M |
| December 31, 2013 | 11.08M |
| December 31, 2012 | 7.135M |
| December 31, 2011 | 6.984M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| DexCom, Inc. | 594.90M |
| Modular Medical, Inc. | 18.30M |
| Senseonics Holdings, Inc. | 31.59M |
| NeuroPace, Inc. | 27.89M |
| Abbott Laboratories | 2.889B |